EGFR and non-small cell lung carcinoma: In this study, 68 patients with advanced NSCLC with EGFR mutations diagnosed and treated at Jiangsu Provincial People’s Hospital and Nanjing Chest Hospital from April 2020 to December 2022 were collected as study subjects to compare the efficacy and safety of almonertinib plus chemotherapy and almonertinib alone, to provide reference for second-line treatment of advanced NSCLC patients.